{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:57:33Z","timestamp":1791244653010,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T00:00:00Z","timestamp":1738454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018336","name":"National Institute for Health Research Health Protection Research Unit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.vaccine.2025.126831","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T11:29:34Z","timestamp":1739359774000},"page":"126831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Modelling the impact and cost effectiveness of universal varicella vaccination in England."],"prefix":"10.1016","volume":"50","author":[{"given":"L.","family":"Adams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Karachaliou Prasinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Trotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2025.126831_bb0005","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1542\/peds.78.4.723","article-title":"Population-Based Studies of Varicella Complications","volume":"78","author":"Guess","year":"1986","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126831_bb0010","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1017\/S0950268800004714","article-title":"Modelling the impact of immunization on the epidemiology of varicella zoster virus","volume":"125","author":"Brisson","year":"2000","journal-title":"Epidemiol Infect"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126831_bb0015","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1517\/14656566.5.3.551","article-title":"Management of herpes zoster (shingles) and postherpetic neuralgia","volume":"5","author":"Johnson","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.vaccine.2025.126831_bb0020","series-title":"The nature of herpes zoster: a long-term study and a new hypothesis","author":"Hope-Simpson","year":"1965"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2025.126831_bb0025","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0264-410X(01)00437-6","article-title":"The cost-effectiveness of varicella vaccination in Canada","volume":"20","author":"Brisson","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126831_bb0030","first-page":"368","article-title":"Risk of herpes zoster after exposure to varicella to explore the exogenous boosting hypothesis: self controlled case series study using UK electronic healthcare data","author":"Forbes","year":"2020","journal-title":"bmj"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126831_bb0035","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/cid\/ciq077","article-title":"Herpes zoster incidence among insured persons in the United States, 1993\u20132006: evaluation of impact of varicella vaccination","volume":"52","author":"Leung","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126831_bb0040","article-title":"Joint committee on vaccination and immunisation Minute of the meeting held on 01 February 2023","author":"JCVI","year":"2023","journal-title":"JCVI"},{"key":"10.1016\/j.vaccine.2025.126831_bb0045","article-title":"Joint committee on vaccination and immunisation minutes from the meeting held on Friday 25th Janurary 2002 at 10:30. Room 102A\/124A, Skipton House","author":"JCVI","year":"2002","journal-title":"JCVI"},{"key":"10.1016\/j.vaccine.2025.126831_bb0050","series-title":"Joint committee on vaccination and immunisation Minute of the meeting held on Wednesday 16 June 2010 10.30am \u2013 4.00pm","author":"JCVI","year":"2010"},{"issue":"10","key":"10.1016\/j.vaccine.2025.126831_bb0055","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/adc.88.10.862","article-title":"Varicella vaccination in England and Wales: cost-utility analysis","volume":"88","author":"Brisson","year":"2003","journal-title":"Arch Dis Child"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126831_bb0060","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.vaccine.2011.11.026","article-title":"The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom","volume":"30","author":"Van Hoek","year":"2012","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2025.126831_bb0065","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.vaccine.2011.01.037","article-title":"Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England","volume":"29","author":"van Hoek","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126831_bb0070","author":"United Nations. World Population Prospects"},{"issue":"Supplement_4","key":"10.1016\/j.vaccine.2025.126831_bb0075","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiac255","article-title":"The Impact of Universal Varicella Vaccination on Herpes Zoster Incidence in the United States: Comparison of Birth Cohorts Preceding and Following Varicella Vaccination Program Launch","volume":"226","author":"Leung","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126831_bb0080","author":"CDC"},{"key":"10.1016\/j.vaccine.2025.126831_bb0085","author":"JCVI. GOV.UK"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126831_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050074","article-title":"Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases","volume":"5","author":"Mossong","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2025.126831_bb0095","series-title":"NHS digital. Childhood Vaccination coverage Statistics - England 2021","year":"2022"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126831_bb0100","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1016\/S2468-2667(17)30234-7","article-title":"Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study","volume":"3","author":"Amirthalingam","year":"2018","journal-title":"Lancet Public Health"},{"issue":"11","key":"10.1016\/j.vaccine.2025.126831_bb0105","doi-asserted-by":"crossref","first-page":"e3617","DOI":"10.1093\/cid\/ciaa1708","article-title":"Epidemiological Impact and Cost-Effectiveness of Varicella Vaccination Strategies in the United Kingdom","volume":"73","author":"Akpo","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126831_bb0115","author":"Jones"},{"key":"10.1016\/j.vaccine.2025.126831_bb0120","author":"CDC. Vaccines for Children Program"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126831_bb0125","first-page":"241","article-title":"The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013","volume":"73","author":"Hobbelen","year":"2016","journal-title":"J Inf Secur"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126831_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282327","article-title":"Systematic review of economic evaluations of varicella vaccination programmes","volume":"18","author":"Anderson","year":"2023","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126831_bb0135","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-068611","article-title":"Epidemiology of hospitalisations due to chickenpox and quality of life lost in community and hospital settings: protocol for a prospective cohort study across two countries","volume":"13","author":"Marlow","year":"2023","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126831_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025553","article-title":"Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme","volume":"9","author":"van Oorschot","year":"2019","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126831_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-018-1094-7","article-title":"The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study","volume":"16","author":"Melegaro","year":"2018","journal-title":"BMC Med"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126831_bb0150","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.clinthera.2015.01.006","article-title":"Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zoster","volume":"37","author":"Littlewood","year":"2015","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126831_bb0155","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/S0950268808000678","article-title":"Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom","volume":"137","author":"Gauthier","year":"2009","journal-title":"Epidemiol Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126831_bb0160","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1080\/14760584.2023.2252065","article-title":"Combined measles-mumps-rubella-varicella vaccine and febrile convulsions: the risk considered in the broad context","volume":"22","author":"Casabona","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.126831_bb0165","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00019053-200321010-00002","article-title":"Economic evaluations of varicella vaccination programmes: a review of the literature","volume":"21","author":"Thiry","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vaccine.2025.126831_bb0170","series-title":"The epidemiology of Hospitalisations due to chickenpox and quality of life lost in community and hospital settings; a prospective cohort study accross two countries","author":"Marlow","year":"2025"},{"key":"10.1016\/j.vaccine.2025.126831_bb0175","author":"NICE"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126831_bb0180","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4161\/hv.18444","article-title":"Evaluation of the establishment of herd immunity in the population by means of serological surveys and vaccination coverage","volume":"8","author":"Plans-Rubi\u00f3","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.126831_bb0185","author":"Lopez"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126831_bb0190","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/oxfordjournals.aje.a117238","article-title":"Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States","volume":"140","author":"Halloran","year":"1994","journal-title":"Am J Epidemiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25001288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25001288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T15:29:38Z","timestamp":1741793378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25001288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":37,"alternative-id":["S0264410X25001288"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126831","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modelling the impact and cost effectiveness of universal varicella vaccination in England.","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126831","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126831"}}